D.Western Therapeutics Institute, Inc. (JP:4576)
:4576
4576 Stock Chart & Stats
¥105.00
-¥3.00(-1.74%)
At close: 4:00 PM EST
¥105.00
-¥3.00(-1.74%)
Day’s Range― - ―
52-Week Range¥87.00 - ¥181.00
Previous CloseN/A
Volume3.18M
Average Volume (3M)623.89K
Market Cap
¥5.22B
Enterprise Value¥3.15B
Total Cash (Recent Filing)¥1.05B
Total Debt (Recent Filing)¥517.95M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding54,356,712
10 Day Avg. Volume615,690
30 Day Avg. Volume623,886
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins indicate strong unit economics and pricing power for the core product set. This creates durable capacity to fund R&D and SG&A as revenue scales, improving the path to sustainable profitability once fixed costs are absorbed.
Narrowing Loss TrendA material reduction in losses year-over-year demonstrates operational progress and tighter cost control. If sustained, this trend extends runway, lowers near-term refinancing pressure, and increases the probability of reaching break-even within a multi-quarter horizon.
Improved LeverageMarked improvement in leverage eases solvency risk and enhances financial flexibility. A stronger balance sheet supports continued investment in development programs and gives management more options for non-dilutive financing or better terms for debt if additional capital is needed.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business cannot self-fund operations and relies on external capital. This structural cash burn elevates dilution or refinancing risk and constrains the company's ability to invest aggressively without securing new funding.
Small, Volatile Revenue BaseA small, inconsistent top line limits economies of scale and makes long-term planning difficult. Volatility in revenue increases execution risk for commercialization and R&D prioritization, reducing predictability of margin expansion and cash generation over the medium term.
Deep UnprofitabilityLosses far in excess of revenue reflect a business still remote from break-even. Persistent negative profitability depresses returns on equity and hinders internally generated capital formation, making the company dependent on external funding and limiting long-term financial resilience.
D.Western Therapeutics Institute News
4576 FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was ¥87.00 and its highest was ¥181.00 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is ¥5.22B.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on Feb 13, 2026. The company reported -¥2.44 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.44.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 54,356,712 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -¥2.44 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in JP:4576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
D.Western Therapeutics Institute, Inc.
D.Western Therapeutics Institute (4576) is a biotechnology company focused on developing innovative therapeutic solutions for various medical conditions. Operating primarily in the healthcare sector, the company specializes in research and development of biologics and small-molecule drugs aimed at treating chronic diseases, particularly in oncology and autoimmune disorders. With a commitment to advancing science and improving patient outcomes, D.Western Therapeutics Institute leverages cutting-edge technology and extensive clinical research to create effective treatment options.